Capital for Cures

Royalty origination across life sciences

We use our own AI models to find royalties and introduce their holders to asset managers and royalty funds, who may buy the royalties or lend against them. Holders may use the money as they choose.

Talk to us Our services
Outside pharma and vaccines
29%
of annual life sciences sales
2%
of royalty financings, 2020 to 2025

Medtech, animal health, and crops and seeds; sales for the latest year available. Sources: IQVIA, Kalorama, AgbioInvestor, HealthforAnimals, Gibson Dunn Royalty Finance Tracker; classification by Capital for Cures. See the data

What we do

A royalty is a share of sales paid for the use of an invention: a 5% royalty on a product selling $200m a year pays the holder $10m a year. Royalty financing turns those future payments into money today.

Royalty financing We review the royalty, prepare it for investors and introduce the holder to asset managers and royalty funds, who may buy it or lend against it. A deal can cover all of a royalty, part of it or one region only. Bundling smaller royalties No royalty is too small. When one cannot be funded on its own, we group it with others into a portfolio that investors can fund. Each holder keeps its own agreement and receives its own payment. Portfolio audits We review the royalties you hold or have bought and check that you are paid what the licence says.

See five worked examples, deal options and royalty terms in plain words on the For royalty holders page.

A financing tool that has barely left pharma

Wherever technology is licensed, royalties are paid: on drugs and vaccines, medical devices, animal medicines, software, and plant varieties and traits. In pharma, holders regularly sell these royalties or borrow against them. In the other areas the instrument works the same way, but few deals are made public. We bring royalties from all six areas to asset managers and royalty funds, and we are working to grow royalty financing across life sciences.

The same instrument in every area
How royalties arise in each area, and how often they have been financed
AreaWhat is licensedHow the royalty is paidFinancings, 2020 to 2025Market
PharmaA drug, licensed to a partner that sells itA percentage of net sales127Established market
VaccinesAn antigen, an adjuvant or a vaccine platformA percentage of sales, or a fee per dose1Rare
MedtechA device design or a component technologyA percentage of device sales2Rare
Animal healthA medicine or vaccine for pets or livestockA percentage of sales1Rare
Digital healthSoftware, an algorithm or a data setA share of licence or subscription revenue0No listed deals
Crops and seedsA plant variety or a genetic traitA fee per unit of seed sold, or a share of sales0No listed deals
Capital for Cures, royalty intelligenceDeals: publicly disclosed royalty financings listed in the Gibson Dunn Royalty Finance Tracker; classification by Capital for Cures

For asset managers and royalty funds

We find royalties in all six areas, prepare the information you need to review them and bundle smaller ones into portfolios. How we work with investors

Our weekly analysis of royalty deals

Read by more than 500 royalty investors, lawyers and dealmakers.

All insights

Talk to us about a royalty or a portfolio

Sebastian Gensior
sebastian@capitalforcures.com
Michał Czarnuch
michal@capitalforcures.com
Book a call
Capital for Cures AG, Schoffelgasse 3, 8001 Zürich, Switzerland